Literature DB >> 16723567

Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Klaudia Kosowska-Shick1, Kim Credito, Glenn A Pankuch, Gengrong Lin, Bülent Bozdogan, Pamela McGhee, Bonifacio Dewasse, Dong-Rack Choi, Jei Man Ryu, Peter C Appelbaum.   

Abstract

DW-224a is a new broad-spectrum quinolone with excellent antipneumococcal activity. Agar dilution MIC was used to test the activity of DW-224a compared to those of penicillin, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, gemifloxacin, amoxicillin-clavulanate, cefuroxime, and azithromycin against 353 quinolone-susceptible pneumococci. The MICs of 29 quinolone-resistant pneumococci with defined quinolone resistance mechanisms against seven quinolones and an efflux mechanism were also tested. DW-224a was the most potent quinolone against quinolone-susceptible pneumococci (MIC(50), 0.016 microg/ml; MIC(90), 0.03 microg/ml), followed by gemifloxacin, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin. beta-Lactam MICs rose with those of penicillin G, and azithromycin resistance was seen mainly in strains with raised penicillin G MICs. Against the 29 quinolone-resistant strains, DW-224a had the lowest MICs (0.06 to 1 microg/ml) compared to those of gemifloxacin, clinafloxacin, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin. DW-224a at 2x MIC was bactericidal after 24 h against eight of nine strains tested. Other quinolones gave similar kill kinetics relative to higher MICs. Serial passages of nine strains in the presence of sub-MIC concentrations of DW-224a, moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin, gemifloxacin, amoxicillin-clavulanate, cefuroxime, and azithromycin were performed. DW-224a yielded resistant clones similar to moxifloxacin and gemifloxacin but also yielded lower MICs. Azithromycin selected resistant clones in three of the five parents tested. Amoxicillin-clavulanate and cefuroxime did not yield resistant clones after 50 days.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723567      PMCID: PMC1479131          DOI: 10.1128/AAC.00153-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Antipneumococcal activity of ABT-773 compared to those of 10 other agents.

Authors:  T A Davies; L M Ednie; D M Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

6.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Authors:  A Tait-Kamradt; T Davies; P C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

Review 9.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

10.  Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.

Authors:  L K McDougal; R Facklam; M Reeves; S Hunter; J M Swenson; B C Hill; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more
  8 in total

1.  Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.

Authors:  R Dias; M Caniça
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

2.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

Review 3.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  High-order combination effects and biological robustness.

Authors:  Joseph Lehár; Andrew Krueger; Grant Zimmermann; Alexis Borisy
Journal:  Mol Syst Biol       Date:  2008-08-05       Impact factor: 11.429

5.  Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.

Authors:  Sara N Richter; Giulia Giaretta; Valentina Comuzzi; Elisabetta Leo; Lesley A Mitchenall; L Mark Fisher; Anthony Maxwell; Manlio Palumbo
Journal:  Nucleic Acids Res       Date:  2007-08-30       Impact factor: 16.971

Review 6.  Pipeline of Known Chemical Classes of Antibiotics.

Authors:  Cristina d'Urso de Souza Mendes; Adelaide Maria de Souza Antunes
Journal:  Antibiotics (Basel)       Date:  2013-12-06

7.  Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.

Authors:  Chin Kook Rhee; Jung Hyun Chang; Eu Gene Choi; Hyun Kuk Kim; Yong-Soo Kwon; Sun Young Kyung; Ji-Hyun Lee; Myung Jae Park; Kwang Ha Yoo; Yeon Mok Oh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-22

Review 8.  Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature.

Authors:  Carly Ching; Ebiowei S F Orubu; Indorica Sutradhar; Veronika J Wirtz; Helen W Boucher; Muhammad H Zaman
Journal:  JAC Antimicrob Resist       Date:  2020-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.